The role of non-profit scientific organizations in European programs for the early detection and prevention of colorectal cancer

Why Screening?

Prevention efforts, such as regular screening and early detection, are critical as colorectal cancer (CRC) often develops from precancerous polyps that can be removed before they become malignant. Risk factors such as age, family history, lifestyle choices, and certain medical conditions contribute to the likelihood of developing CRC, but proactive measures like regular screenings, healthy diet, exercise, and smoking cessation significantly reduce risk.

ONCOSCREEN’s Role

Programs like ONCOSCREEN play a crucial role in addressing this public health challenge by increasing awareness, improving access to screenings, and facilitating early diagnosis. ONCOSCREEN focuses on utilizing innovative screening techniques, promoting education, and encouraging individuals to undergo timely CRC screenings. This is because early detection through programs can lead to more effective treatment and improved survival rates, as CRC is far more treatable in its early stages.

Additionally, such programs help alleviate the economic burden associated with late-stage cancer treatments, which are often expensive and less effective. By leveraging technological advancements in screening methods, including non-invasive stool-based tests and advanced imaging techniques, ONCOSCREEN ensures that more people can access convenient, reliable and non-invasive screening options. Furthermore, by integrating genetic screening for individuals with a family history of CRC, ONCOSCREEN further enhances early detection efforts. Moreover, increasing public education on risk factors, symptoms, and the importance of screening fosters a proactive approach to CRC prevention which is crucial for early detection.

As technology continues to advance, incorporating artificial intelligence and digital health tools into screening programs will further enhance early detection capabilities. Specifically in the field of artificial intelligence there is an emerging role for diagnosis of early lesions in endoscopy and other imaging techniques. Increasing funding for research and development in this field of CRC prevention can also lead to improved diagnostic tools and more effective treatment strategies.

The Importance of Public-Private Partnerships

Public-private partnerships can enhance the reach and effectiveness of these programs by providing funding, resources, and innovative solutions to increase screening rates. This is the core of ONCOSCREEN, where the collaboration of scientific and social partners is of pivotal role for the development of new diagnostic tools and their dissemination to the general public. Investing in and expanding such programs such as ONCOSCREEN is essential to saving lives, reducing healthcare costs, and ultimately eradicating colorectal cancer as a major public health threat.

ONCOSCREEN and the Hellenic Society of Gastrointestinal Oncology

In this context, the Hellenic Society of Gastrointestinal Oncology (HSGO) plays a pivotal role as a consultant to the ONCOSCREEN program. Established in 1998, HSGO is an independent national group comprising physicians and researchers with a dedicated interest in digestive oncology. Its primary focus is the diagnosis, prevention, and treatment of malignant neoplasms within the digestive system.

As an ONCOSCREEN partner, HSGO’s responsibilities are multifaceted. One of its key roles involves supporting the collection of end-users’ needs and requirements. By engaging with both healthcare professionals and patients, HSGO ensures that the solutions developed are user-centric and address real-world challenges in CRC screening. This co-creation approach is crucial for tailoring interventions that are both effective and widely accepted within their context. Furthermore, HSGO is actively involved in evaluating the effectiveness of the ONCOSCREEN solutions through clinical trials. By conducting rigorous assessments, HSGO provides valuable insights into the practical application and impact of new screening methodologies. This evidence-based evaluation is essential for validating the efficacy of innovative approaches to screening before they are integrated into standard clinical practice.

Another significant contribution of HSGO is its involvement in the development of the ONCOSCREEN living guidelines for the screening and early diagnosis of colorectal cancer. These guidelines are a set of dynamic documents that evolve based on emerging evidence and technological advancements. HSGO’s expertise ensures that the guidelines remain current, relevant, and reflective of the latest research findings, thereby aiding clinicians in making informed decisions regarding CRC screening and management.

Dissemination and communication are also central to HSGO’s role within the program. The society leverages its extensive network to promote awareness about ONCOSCREEN’s objectives and findings. Through organizing scientific events, workshops, and public awareness campaigns, HSGO facilitates the exchange of knowledge among healthcare professionals and educates the public on the importance of early CRC detection. HSGO has a history of organizing these educational activities, such as training courses in advanced endoscopy, which underscore its commitment to professional development and public health education.

Conclusion

In summary, the Hellenic Society of Gastrointestinal Oncology serves as a cornerstone in the ONCOSCREEN program. Its comprehensive involvement—from needs assessment and clinical evaluation to guideline development and public outreach—ensures that the program is both scientifically robust and socially impactful. Through its dedicated efforts, HSGO significantly contributes to advancing colorectal cancer prevention and care, ultimately aiming to reduce the burden of this disease across Europe.